Eurofins Successfully Prices New €600m 7-Year 4%-Coupon Senior Unsecured Bonds
2022年6月22日 - 3:14AM
ビジネスワイヤ(英語)
Regulatory News:
Eurofins Scientific (Paris:ERF) (EUFI.PA, rated Baa3/positive by
Moody’s and BBB/stable- by Fitch, “Eurofins”), a global
leader in bioanalytical testing, announces that it has successfully
raised €600m in its latest senior unsecured Euro-denominated public
bond issuance (the “Bonds”). The Bonds have a 7-year
maturity (due on 6 July 2029) and will bear an annual fixed rate
coupon of 4%. The transaction was well received and was more than
2.3x over-subscribed.
As announced this morning, the use of proceeds of those bonds is
to proactively manage the repurchase of Eurofins’ €300m Deeply
Subordinated Fixed to Floating rate bonds (ISIN: XS2051471105)
issued 11 September 2019 with a first call date in August 2022 (the
"2022 Hybrid Bonds") and its €300m Deeply Subordinated Fixed
to Floating rate bonds (ISIN: XS1224953882) issued 29 April 2015
with a first call date in April 2023 (the "2023 Hybrid
Bonds") that are currently under tender offers.
Comment from the CEO, Dr. Gilles Martin: “We are very
pleased with the results of our latest public bond issuance, which
demonstrates again the confidence from Eurofins’ investors despite
a difficult market environment.”
The Bonds will be listed from their issue date (29 June 2022) on
the regulated market of the Luxembourg stock exchange (ISIN
XS2491664137). The Bonds are not registered under the US Securities
Act of 1933 as amended (the “Securities Act”) and may not be
offered or sold in (i) the United States (as such term is defined
in Regulation S under the Securities Act) unless registered under
the Securities Act or pursuant to an exemption from such
registration nor (ii) in any other jurisdiction where it is
unlawful to do so.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. Eurofins is the global leader in
food, environment, pharmaceutical and cosmetic product testing, and
in discovery pharmacology, forensics, advanced material sciences
and agroscience Contract Research services. Eurofins is also a
market leader in certain testing and laboratory services for
genomics, and in the support of clinical studies, as well as in
BioPharma Contract Development and Manufacturing. The Group also
has a rapidly developing presence in highly specialised and
molecular clinical diagnostic testing and in-vitro diagnostic
products.
With 58,000 staff across a decentralised and entrepreneurial
network of 900 laboratories in 54 countries, Eurofins offers a
portfolio of over 200,000 analytical methods to evaluate the
safety, identity, composition, authenticity, origin, traceability
and purity of a wide range of products, as well as providing
innovative clinical diagnostic testing services and in-vitro
diagnostic products.
The Group’s objective is to provide its customers with
high-quality services, innovative solutions and accurate results on
time. Eurofins is ideally positioned to support its clients’
increasingly stringent quality and safety standards and the
increasing demands of regulatory authorities as well as the
requirements of healthcare practitioners around the world.
In 2020 and 2021, Eurofins reacted quickly to meet the global
challenge of COVID-19, by creating the capacity to help over 20
million patients monthly who may have been impacted by the pandemic
with our testing products and our services and directly supporting
healthcare professionals working on the front line to fight the
virus. The Group has established widespread PCR testing
capabilities and has carried out over 40 million tests in its own
laboratories, is supporting the development of a number of vaccines
and has established its SAFER@WORK™ testing, monitoring and
consulting programmes to help ensure safer environments, travel and
events during COVID-19.
Eurofins has grown very strongly since its inception and its
strategy is to continue expanding its technology portfolio and its
geographic reach. Through R&D and acquisitions, the Group draws
on the latest developments in the field of biotechnology and
analytical chemistry to offer its clients unique analytical
solutions.
Shares in Eurofins Scientific are listed on the Euronext Paris
Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF
FP).
Until it has been lawfully made public widely by Eurofins
through approved distribution channels, this document contains
inside information for the purpose of Regulation (EU) 596/2014 of
the European Parliament and of the Council of 16 April 2014 on
market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific’s management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantees can be made as to their completeness
or validity.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220621006017/en/
Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620
E-mail: ir@eurofins.com www.eurofins.com
Enerplus (NYSE:ERF)
過去 株価チャート
から 6 2024 まで 7 2024
Enerplus (NYSE:ERF)
過去 株価チャート
から 7 2023 まで 7 2024